Ascelia Pharma completes FDA Type A meeting on Orviglance NDA
Ascelia Pharma completed a previously scheduled Type A meeting with the FDA on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance New Drug Application (NDA). The meeting was held to discuss the issues raised by the CRL.
Story updates
05:45:02 AM UTC
SquawkNews
ACE - Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.